NRx Pharmaceuticals
Filed with the SEC on · accession 0001437749-26-035303
NRXP filed a DEF 14A (proxy statement) with the SEC on Nov 5, 2026. Information for the shareholder meeting: votes, board members and executive pay. The stock moved -8.8% by the first close after the filing.
NRx Pharmaceuticals filed a definitive proxy statement for its 2026 annual meeting, asking stockholders to elect Dennis McBride as a Class II director and ratify Weinberg & Company as independent auditors for fiscal year 2026.
Close before
$2.49
Nov 4, 2026
First close after
-8.84%
$2.27
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for NRXP, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for NRXP?
Click hereNRXP filed a DEF 14A (Board change). NRx Pharmaceuticals filed a definitive proxy statement for its 2026 annual meeting, asking stockholders to elect Dennis McBride as a Class II director and ratify Weinberg & Company as independent auditors for fiscal year 2026.
Not always. A planned retirement with a successor is usually calm; a sudden departure “effective immediately”, especially of a CFO or near results, often worries investors.
Information for the shareholder meeting: votes, board members and executive pay. Executive pay tables show how management is paid. Check the items shareholders vote on (mergers, new share plans).
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A DEF 14A (proxy statement): Information for the shareholder meeting: votes, board members and executive pay.
NRXP closed at $2.49 before the filing and $2.27 on Nov 5, 2026 (-8.84%).
Get alerts when NRXP files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days